ARDS News and Press, Aridis Pharmaceuticals Inc. From 02/17/23

ORLANDO, FL / ACCESSWIRE / February 17, 2023 / RedChip Companies will air new interviews with Rail Vision Ltd. (Nasdaq:RVSN), Aridis Pharmaceuticals, Inc. (Nasdaq:ARDS), and Digital Ally, Inc. (NASDAQ:DGLY) on The RedChip Money Report® on Bloomberg TV, this Saturday, February 18, at 7 p.m. ...

Aridis Pharmaceuticals ( NASDAQ: ARDS ) monoclonal antibody therapy AR-301 failed the main goal in a phase 3 trial to treat Ventilator Associated Pneumonia (VAP) caused by Gram-positive bacteria Staphylococcus aureus (S. aureus). The study, dubbed AR-301-002, evalu...

LOS GATOS, Calif, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced top-line results from the AR-301-002 Phase 3 study, which evaluated the superiority of adjunctive use of the investigational monoclonal antibody candidate AR-301 with standard of care (...

AR-501 is an inhaled formulation of gallium citrate with broad-spectrum anti-infective activity being developed to treat chronic lung infections in CF patients Los Gatos, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) , a biopharmaceutica...

Los Gatos, Calif., Dec. 28, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) , a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, will host a conference call and audio-only webc...

Los Gatos, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) , a biopharmaceutical company today announced the Cystic Fibrosis Foundation invested $4.85 million in Aridis common stock on market terms under NASDAQ rules to support the ongoing developme...

Nano-cap biotech Aridis Pharmaceuticals ( NASDAQ: ARDS ) announced Monday that Cystic Fibrosis Foundation invested $4.85M in the company’s common stock in support of ongoing studies for the anti-microbial drug AR-501. With the investment, the financial backing made by Cystic Fi...

Los Gatos, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) , a biopharmaceutical company today announced the Cystic Fibrosis Foundation invested $4.85 million in Aridis common stock on market terms under NASDAQ rules to support the ongoing developme...

The Sudan Ebola and Marburg mAb programs were awar d ed approximately $ 190 million of BARDA funding covering manufacturing, efficacy and safety evaluations, and regulatory approval Los Gatos, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Aridis...

A California-based %Biotech company turned heads on Wednesday after the company announced the closing of patient enrollment in the multiple ascending dose (MAD) and dose-ranging cohorts in the Phase 2a clinical trial of AR-501 in %CysticFibrosis (CF) patients. According to the release, th...